AxoGen is an industry growth leader with 26% YoY revenue growth, positive free cash flow despite a GAAP loss and a wide moat. At $49.37 the price is only 2.8% below the $50.78 analyst target with RSI at 81, so the 0.19 reward-to-risk offers little room.
Thesis pillars
- Fcf Positive Despite Gaap Loss→Stable
- Industry Growth Leader↓Deteriorating
- Limited Upside To Analyst Target→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 1, 2026, based on the 10-K filed Feb 24, 2026
AxoGen, Inc. (AXGN) Stock Analysis
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $51.35, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (2.9% away).
AxoGen develops and commercializes peripheral nerve repair products including Avance Nerve Graft, Axoguard Nerve Connector and Protector, and Avive+ Soft Tissue Matrix, sold primarily in the U.S. Approximately 60% of revenues derive from the Avance product family, with... Read more
Hold if already holding. Not a fresh buy at $51.35, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (2.9% away). Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Score 5.7/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 109d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About AxoGen, Inc.
About AxoGen, Inc.
AxoGen received FDA biologics license approval for Avance on December 3, 2025 — the first BLA-approved acellular nerve scaffold for peripheral nerve repair — with commercial availability expected in early Q2 2026. The company's seven-product portfolio addresses a total addressable market estimated at $5.6 billion; approximately 60% of revenues come from Avance Products, with the remainder from Axoguard and Avive+ lines sold in the U.S., Canada, Germany, the United Kingdom, Spain and several other countries.
AxoGen earns revenue through direct sales to hospitals and ambulatory surgery centers, with reimbursement driven by Category I CPT codes 64912 and +64913, established in January 2018. Effective January 1, 2026, CMS created a new Ambulatory Payment Category 5433 for level 3 nerve repair, improving reimbursement for Avance Nerve Graft procedures by 96% in hospital outpatient centers and 221% in ambulatory surgery centers versus 2019 levels. The Axoguard Nerve Connector and Nerve Protector are distributed exclusively through an agreement with Evergen through December 31, 2030; Evergen also manufactures Axoguard HA+ Nerve Protector and Axoguard Nerve Cap. Avance is processed at the company's APC Facility in Vandalia, Ohio, with terminal sterilization performed by a single third-party contractor. The TAM spans extremities ($2.9 billion), oral maxillofacial ($1.2 billion), breast ($677 million) and urology ($754 million).
Show full overview
Portions of the FDA's December 3, 2025 BLA approval were granted under the accelerated approval pathway: continued authorization for sensory nerve discontinuities greater than 25mm and for mixed and motor nerve discontinuities is contingent on a post-marketing confirmatory study. The FDA requires a final protocol by February 5, 2026, study completion by December 5, 2030, and a final report by June 5, 2031, with progress reports every 180 days starting May 31, 2026. If AxoGen fails to complete the study on schedule or to verify clinical benefit, the FDA may withdraw those indications on an expedited basis — a binary outcome for the product line accounting for approximately 60% of total revenue.
See also: Healthcare · Medical Devices
From AxoGen, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated Oct 29, 2026Recent Developments — AxoGen, Inc.
Latest news
- NEWS AXGN Maintained by Leerink Partners -- Price Target Raised to $5 - GuruFocus — GuruFocus Oct 29, 2026 positive
- NEWS Does Axogen (AXGN) Have More Upside Or Is It Fully Priced? - Yahoo Finance — Yahoo Finance Oct 28, 2026 positive
- NEWS Axogen, Inc. Stock 12‑Month Price Target Raised to $54, Implies 44% Upside - TradingView — TradingView Oct 28, 2026 positive
- NEWS AxoGen Q3 Earnings Call Highlights - TradingView — TradingView Oct 28, 2026 neutral
- NEWS Mizuho raises AxoGen stock price target to $65 on growth outlook - Investing.com Nigeria — Investing.com Nigeria Oct 28, 2026 positive
Latest item Oct 29, 2026 · Generated 2026-11-05T11:44:07Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $51.35, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (2.9% away). Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Analyst target $51.41 (+0.1%), stop $47.76 (−7.5%), A.R:R 0.0:1. Score 5.7/10, moderate confidence.
Analyst target: $51.41 (+0.1% upside). Analyst target $51.41 (+0.1%), stop $47.76 (−7.5%), A.R:R 0.0:1. Stop-loss: $47.76.
Analyst target reached - limited upside remaining; Near 52-week high (2.9% away); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2).
AxoGen, Inc. trades at a P/E of N/A (forward 72.8). TrendMatrix value score: 4.2/10. Verdict: Hold.
17 analysts rate AXGN, with a consensus score of 4.2/5. 11 analysts publish price targets averaging $59.
What does AxoGen, Inc. do?AxoGen develops and commercializes peripheral nerve repair products including Avance Nerve Graft, Axoguard Nerve...
AxoGen develops and commercializes peripheral nerve repair products including Avance Nerve Graft, Axoguard Nerve Connector and Protector, and Avive+ Soft Tissue Matrix, sold primarily in the U.S. Approximately 60% of revenues derive from the Avance product family, with reimbursement supported by Category I CPT codes established in 2018. The Axoguard line is sourced exclusively through a distribution and manufacturing agreement with Evergen expiring December 31, 2030.